If a Phase II trial demonstrates that a treatment is both effective and reasonably safe, the next step is often a Phase III trial. Phase III trials involve a larger patient population and aim to provide definitive evidence of the treatment's efficacy and safety. If the results of the Phase II trial are not promising, the treatment may be abandoned or sent back for further preclinical research.
